The α-SMA+MVND/CD34+ MVND ratio increased from 35.57% in grade II to 76.36% in grade IV (Table 2), suggesting the preferential proliferation of pericytes and more pericyte-contained MVs in high grade glioma. The gene discussed is ACTA1; the disease is central nervous system cancer.